Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)

      Highlights

      • This is a special issue of “Metabolism” dedicated to nonalcoholic fatty liver disease.
      • Experts in the field provide an overview of recent progress and developments in NAFLD and offer their expert opinion on future directions.
      • NAFLD remains a highly prevalent disease without an approved treatment.

      Abbreviations:

      FIB-4 (fibrosis-4), HCC (hepatocellular carcinoma), IR (insulin resistance), MAFLD (metabolic associated fatty liver disease), MetS (metabolic syndrome), NAFLD (nonalcoholic fatty liver disease), NASH (nonalcoholic steatohepatitis), PPAR (peroxisome proliferator activated receptor), T2DM (type 2 diabetes mellitus)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Polyzos S.A.
        • Bugianesi E.
        • Kountouras J.
        • Mantzoros C.S.
        Nonalcoholic fatty liver disease: updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-gamma agonists.
        Metabolism. 2017; 66: 64-68
        • Polyzos S.A.
        • Kountouras J.
        • Mantzoros C.S.
        Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics.
        Metabolism. 2019; 92: 82-97
        • Athyros V.G.
        • Polyzos S.A.
        • Kountouras J.
        • Katsiki N.
        • Anagnostis P.
        • Doumas M.
        • et al.
        Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.
        Curr Vasc Pharmacol. 2020; 18: 172-181
        • Katsiki N.
        • Mikhailidis D.P.
        • Mantzoros C.S.
        Non-alcoholic fatty liver disease and dyslipidemia: an update.
        Metabolism. 2016; 65: 1109-1123
        • Lonardo A.
        • Sookoian S.
        • Pirola C.J.
        • Targher G.
        Non-alcoholic fatty liver disease and risk of cardiovascular disease.
        Metabolism. 2015; 65: 1136-1150
        • Fazel Y.
        • Koenig A.B.
        • Sayiner M.
        • Goodman Z.D.
        • Younossi Z.M.
        Epidemiology and natural history of nonalcoholic fatty liver disease.
        Metabolism. 2016; 65: 1017-1025
        • Younossi Z.
        • Anstee Q.M.
        • Marietti M.
        • Hardy T.
        • Henry L.
        • Eslam M.
        • et al.
        Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
        Nat Rev Gastroenterol Hepatol. 2018; 15: 11-20
        • Reccia I.
        • Kumar J.
        • Akladios C.
        • Virdis F.
        • Pai M.
        • Habib N.
        • et al.
        Non-alcoholic fatty liver disease: a sign of systemic disease.
        Metabolism. 2017; 72: 94-108
        • Paik J.M.
        • Golabi P.
        • Biswas R.
        • Alqahtani S.
        • Venkatesan C.
        • Younossi Z.M.
        Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States.
        Hepatol Commun. 2020; 4: 890-903
        • Younossi Z.M.
        • Tampi R.P.
        • Racila A.
        • Qiu Y.
        • Burns L.
        • Younossi I.
        • et al.
        Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S.
        Diabetes Care. 2020; 43: 283-289
        • Polyzos S.A.
        • Mantzoros C.S.
        Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease.
        Metabolism. 2014; 63: 161-167
        • Mintziori G.
        • Polyzos S.A.
        Emerging and future therapies for nonalcoholic steatohepatitis in adults.
        Expert Opin Pharmacother. 2016; 17: 1937-1946
        • Barb D.
        • Portillo-Sanchez P.
        • Cusi K.
        Pharmacological management of nonalcoholic fatty liver disease.
        Metabolism. 2016; 65: 1183-1195
        • Polyzos S.A.
        • Mantzoros C.S.
        Nonalcoholic fatty future disease.
        Metabolism. 2016; 65: 1007-1016
        • Kechagias S.
        • Nasr P.
        • Blomdahl J.
        • Ekstedt M.
        Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.
        Metabolism. 2020; https://doi.org/10.1016/j.metabol.2020.154183:154183
        • Dewidar B.
        • Kahl S.
        • Pafili K.
        • Roden M.
        Metabolic liver disease in diabetes - from mechanisms to clinical trials.
        Metabolism. 2020; https://doi.org/10.1016/j.metabol.2020.154299:154299
        • Long M.T.
        • Gandhi S.
        • Loomba R.
        Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.
        Metabolism. 2020; https://doi.org/10.1016/j.metabol.2020.154259:154259
        • Perakakis N.
        • Polyzos S.A.
        • Yazdani A.
        • Sala-Vila A.
        • Kountouras J.
        • Anastasilakis A.D.
        • et al.
        Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study.
        Metabolism. 2019; 101: 154005
        • Perakakis N.
        • Stefanakis K.
        • Mantzoros C.S.
        The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.
        Metabolism. 2020;
        • Mukherji A.
        • Dachraoui M.
        • Baumert T.F.
        Perturbation of the circadian clock and pathogenesis of NAFLD.
        Metabolism. 2020;
        • Mantovani A.
        • Scorletti E.
        • Mosca A.
        • Alisi A.
        • Byrne C.D.
        • Targher G.
        Complications, morbidity and mortality of nonalcoholic fatty liver disease.
        Metabolism. 2020; https://doi.org/10.1016/j.metabol.2020.154170:154170
        • Majumdar A.
        • Tsochatzis E.A.
        Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease.
        Metabolism. 2020; https://doi.org/10.1016/j.metabol.2020.154291:154291
        • EASL–EASD–EASO
        EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
        Diabetologia. 2016; 59: 1121-1140
        • Chalasani N.
        • Younossi Z.
        • Lavine J.E.
        • Charlton M.
        • Cusi K.
        • Rinella M.
        • et al.
        The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.
        Hepatology. 2018; 67: 328-357
        • Athyros V.G.
        • Alexandrides T.K.
        • Bilianou H.
        • Cholongitas E.
        • Doumas M.
        • Ganotakis E.S.
        • et al.
        The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
        Metabolism. 2017; 71: 17-32
        • Polyzos S.A.
        • Kang E.S.
        • Boutari C.
        • Rhee E.J.
        • Mantzoros C.S.
        Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
        Metabolism. 2020; https://doi.org/10.1016/j.metabol.2020.154203:154203
        • Polyzos S.A.
        • Mantzoros C.S.
        Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review.
        Metabolism. 2016; 65: 1297-1306
        • Eslam M.
        • Sanyal A.J.
        • George J.
        MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.
        Gastroenterology. 2020; 158: 1999-2014
        • Eslam M.
        • Newsome P.N.
        • Sarin S.K.
        • Anstee Q.M.
        • Targher G.
        • Romero-Gomez M.
        • et al.
        A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.
        J Hepatol. 2020; 73: 202-209
        • Buzzetti E.
        • Pinzani M.
        • Tsochatzis E.A.
        The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
        Metabolism. 2016; 65: 1038-1048
        • Polyzos S.A.
        • Kountouras J.
        • Zavos C.
        The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease.
        Hippokratia. 2009; 13: 127
        • Polyzos S.A.
        • Kountouras J.
        • Zavos C.
        • Deretzi G.
        Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease.
        J Clin Gastroenterol. 2012; 46: 272-284
        • Balmer M.L.
        • Dufour J.F.
        Non-alcoholic steatohepatitis - from NAFLD to MAFLD.
        Ther Umsch. 2011; 68: 183-188
        • Younossi Z.M.
        • Rinella M.E.
        • Sanyal A.
        • Harrison S.A.
        • Brunt E.
        • Goodman Z.
        • et al.
        From NAFLD to MAFLD: implications of a premature change in terminology.
        Hepatology. 2020; https://doi.org/10.1002/hep.31420
        • Cusi K.
        Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes.
        Diabetes Care. 2020; 43: 275-279
        • Sumida Y.
        • Okanoue T.
        • Nakajima A.
        Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis.
        Hepatol Res. 2019; 49: 1256-1262
        • Polyzos S.A.
        • Kountouras J.
        • Anastasiadis S.
        • Doulberis M.
        • Katsinelos P.
        Nonalcoholic fatty liver disease: is it time for combination treatment and a diabetes-like approach?.
        Hepatology. 2018; 68: 389
        • Adams L.A.
        • Chan W.K.
        Noninvasive tests in the assessment of NASH and NAFLD fibrosis: now and into the future.
        Semin Liver Dis. 2020; https://doi.org/10.1055/s-0040-1713006
        • Taylor R.S.
        • Taylor R.J.
        • Bayliss S.
        • Hagström H.
        • Nasr P.
        • Schattenberg J.M.
        • et al.
        Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
        Gastroenterology. 2020; 158 (e12): 1611-1625
        • Ampuero J.
        • Aller R.
        • Gallego-Durán R.
        • Crespo J.
        • Calleja J.L.
        • García-Monzón C.
        • et al.
        Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
        J Hepatol. 2020; 73: 17-25
        • Gehrke N.
        • Schattenberg J.M.
        Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?.
        Gastroenterology. 2020; 158: 1929-1947
        • Ji D.
        • Qin E.
        • Xu J.
        • Zhang D.
        • Cheng G.
        • Wang Y.
        • et al.
        Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study.
        J Hepatol. 2020; https://doi.org/10.1016/j.jhep.2020.03.044
        • Targher G.
        • Mantovani A.
        • Byrne C.D.
        • Wang X.B.
        • Yan H.D.
        • Sun Q.F.
        • et al.
        Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
        Gut. 2020; https://doi.org/10.1136/gutjnl-2020-321611
        • Palaiodimos L.
        • Kokkinidis D.G.
        • Li W.
        • Karamanis D.
        • Ognibene J.
        • Arora S.
        • et al.
        Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York.
        Metabolism. 2020; 108: 154262
        • Muscogiuri G.
        • Pugliese G.
        • Barrea L.
        • Savastano S.
        • Colao A.
        Commentary: obesity: the "Achilles heel" for COVID-19?.
        Metabolism. 2020; 108: 154251
        • Zheng K.I.
        • Gao F.
        • Wang X.B.
        • Sun Q.F.
        • Pan K.H.
        • Wang T.Y.
        • et al.
        Letter to the Editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
        Metabolism. 2020; 108: 154244
        • Hussain A.
        • Vasas P.
        • El-Hasani S.
        Letter to the Editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
        Metabolism. 2020; 108: 154256
        • Kong W.
        • Zhang J.
        • Xu Y.
        • Li L.
        • Li Q.
        • Yang L.
        • et al.
        Letter to the Editor: fasting plasma glucose associated with mortality rate in T2DM patients with COVID-19 infection.
        Metabolism. 2020; 108: 154255
        • Angelidi A.M.
        • Belanger M.J.
        • Mantzoros C.S.
        Commentary: COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next.
        Metabolism. 2020; 107: 154245
        • Boettler T.
        • Newsome P.N.
        • Mondelli M.U.
        • Maticic M.
        • Cordero E.
        • Cornberg M.
        • et al.
        Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.
        JHEP Rep. 2020; 2: 100113
        • Polyzos S.A.
        • Kountouras J.
        • Deretzi G.
        • Zavos C.
        • Mantzoros C.S.
        The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.
        Curr Mol Med. 2012; 12: 68-82